An independent peptide reference — no sellers, every claim sourced

Epitalon

Also known as Epithalon, Epithalone, AEDG peptide

Synthetic tetrapeptide from Russian bioregulator research, with contested claims about telomerase and lifespan.

preclinical Neuro & cognition research chemical

At a glance

Category
Neuro & cognition
Status
research chemical
Route
subcutaneous, intramuscular, intraperitoneal, intranasal, sublingual and (parabulbar) around the eye in the published studies
Half-life
No published pharmacokinetics in humans or animals. The peptide contains no D-amino acids, cyclisation, N-methylation or C-terminal amidation - nothing that confers protease resistance - so survival in plasma is presumably measured in minutes. Every circulating half-life figure is extrapolation without a primary source.
Onset
No validated pharmacodynamic onset time; the claimed mechanisms are transcriptional and telomere-directed and would take weeks
Molecular weight
390.35 g/mol
Sequence
Ala-Glu-Asp-Gly

As far as can be established, synthetic epitalon is not registered as a medicine anywhere. The claim that it is 'approved in Russia' conflates three different things: Epithalamine (a bovine pineal extract) has held a pharmaceutical registration in Russia, Endoluten and the Cytomax capsules are registered in Russia as food supplements (BAD, a notification regime without any efficacy assessment), and the synthetic tetrapeptide itself is not a registered medicine. PeptideX has not been able to open the Russian register from outside Russia to confirm this, so the registration should be read as an unverified claim rather than an established fact. No EMA or FDA approval.

Doping status: Not listed by name; as a non-approved substance it falls under S0 and is therefore prohibited at all times

Checked against the WADA 2026 Prohibited List. For a specific product and country, Global DRO is the lookup athletes are expected to use — the List names substances, not brand names.

Mechanism of action

Epitalon is a synthetic tetrapeptide that Khavinson's group at the St Petersburg Institute of Bioregulation and Gerontology proposed as the active constituent of Epithalamine, a crude low-molecular-weight extract of the bovine pineal gland. It falls under the doctrine of 'peptide bioregulators': short peptides from an organ are said to selectively restore the function of that same organ by binding to DNA and directing gene expression.

That tissue specificity is the central and least substantiated assumption of the programme. There is no accepted mechanism by which a peptide of three or four residues, chemically indistinguishable from ordinary proteolytic breakdown material found throughout the body, would selectively navigate to one organ.

The most striking claim is activation of telomerase. In 2003 Khavinson's group reported that epithalon induced hTERT expression, telomerase activity and telomere elongation in telomerase-negative human fetal fibroblasts 1. That finding stood for more than twenty years without replication - an extraordinary claim resting on a single paper in a Russian institute journal, with no mechanism for derepressing one of the most tightly silenced promoters in somatic cells.

In 2025 an independent replication did appear (Brunel University London): in normal fibroblasts and epithelial cells, telomere length and telomerase activity increased, and in two breast cancer cell lines hTERT mRNA rose sharply without an increase in enzyme activity, with activation of ALT (alternative lengthening of telomeres) instead 6. This is the first transparent Western support for the core cell-biology claim. The limitations are substantial, however: two-dimensional cell culture only 6, and the paper was followed by a correction in which figures 1, 2 and 3 were replaced 7.

The hypothesis that these peptides enter nuclei and bind sequence-specifically to promoter DNA (with a preference for CAG-rich motifs) rests almost entirely on work by the original group. Genuine sequence-specific DNA recognition in biology requires a folded domain making several contacts at once, such as a zinc finger or helix-turn-helix. Moreover AEDG carries a net negative charge - the wrong direction for affinity with polyanionic DNA. This should be labelled a hypothesis, not a mechanism.

What the research shows

The evidence consists of an interesting cell culture finding that has now been independently replicated once, a modest mouse study that specifically did not extend mean lifespan, and a series of human outcome claims from a single research group whose effect sizes are not credible and whose methodology cannot be assessed. Nothing demonstrates that epitalon extends healthy human lifespan, and nothing demonstrates that it is safe over years.

Research in humans

The most-cited human claim comes from Khavinson and Morozov (2003): 266 people over 60 years old, followed for 6 to 8 years, treated with Thymalin and/or Epithalamine, with reported mortality reductions of 1.6 to 1.8 fold for Epithalamine and 4.1 fold for the combination with six years of annual administration 3. These figures are simply not credible. A 4.1-fold mortality reduction in an elderly cohort exceeds anything medicine has ever achieved - more than statins, antihypertensives and smoking cessation combined. There is also a reported study in 162 patients with retinitis pigmentosa (5 mcg per eye, parabulbar, 10 days) 5. Visual acuity rose by 0.15-0.20 on average; it was the peripheral visual field that extended in every patient, with 64.8% gaining 90-120 degrees. Both are subjective, effort-dependent measurements taken unblinded in a degenerative condition, which makes a result this uniform a warning sign rather than a strength. And a study in 75 women (0.5 mg per day sublingually, 20 days) reported 1.6 times more melatonin synthesis than placebo, reported at review level without the details needed to judge quality 5.

Animal and lab research

The key study is Anisimov, Khavinson and colleagues (2003) in female SHR mice: 54 animals per group, 1.0 mcg per mouse subcutaneously, five consecutive days per month from three months of age until natural death 2. The result is systematically misrepresented by sellers. Mean lifespan did NOT increase 2. The lifespan of the last 10% of survivors rose 13.3% and maximum lifespan 12.3% 2. Chromosomal aberrations in bone marrow fell 17.1% 2. Total spontaneous tumour incidence did NOT change; leukaemia was inhibited sixfold 2. Tail-of-distribution and maximum-lifespan measures are statistically fragile: maximum lifespan is a statistic of a single animal, and 'the last 10%' of 54 animals is five. Further animal claims (lifespan in Drosophila, CBA mice, HER-2/neu mice, LIO rats) all come from the same group.

Caveats. The human studies are structurally unassessable: the randomisation method, allocation concealment and blinding cannot be verified; treated groups received annual injection courses and therefore repeated clinical contact that the control group did not, which by itself can produce large apparent mortality differences; nothing is reported about attrition over six to eight years of follow-up, while differential attrition manufactures mortality differences; there is no registered protocol and no pre-specified primary endpoint across a wide range of reported outcomes. Everything comes from one research group, published in journals with limited external scrutiny, without any independent replication in more than twenty years. Moreover the human mortality research involved Epithalamine (the crude bovine extract), not the synthetic tetrapeptide - that transfer is an inference, not a finding. A 2025 review article states explicitly that additional short- and long-term toxicity research is needed before approval can be considered 5.

What it is used for

  • Presented as a geroprotector and anti-ageing agent - a claim the evidence does not support
  • Studied in retinitis pigmentosa in an unblinded Russian study of 162 patients, 5.0 mcg per eye parabulbarly for 10 days 5
  • Studied in the regulation of melatonin and the sleep-wake rhythm, in 75 women at 0.5 mg per day sublingually for 20 days 5
  • Self-administered in courses on the grey market, without a validated indication or dose

Dosing

Dose
No two published figures here describe the same thing, so none of them is 'the' dose. The mouse lifespan study gave 1.0 mcg per mouse subcutaneously, about 30-40 mcg/kg, on five consecutive days each month. The retinitis pigmentosa study gave 5.0 mcg per eye by parabulbar injection for 10 days - a local dose into the eye, not a systemic one. The melatonin study in 75 women gave 0.5 mg per day sublingually for 20 days, and it is the only human systemic figure in the review literature. Cell culture work used 0.1-1.0 mcg/ml, which is a concentration in a dish and not a dose at all. Separately from all of these, user protocols circulate 5-10 mg per day subcutaneously.
Frequency
In user protocols once daily
Route
subcutaneous in user protocols
Duration
In user protocols courses of 10-20 consecutive days, repeated one to two times per year
  • This is the heart of the problem, provided it is framed in the right units: in absolute terms user protocols use several thousand times the 1.0 mcg given per mouse in the lifespan study 2, but a human outweighs a mouse thousands of times over, so per kilogram the user dose (roughly 70-140 mcg/kg at 5-10 mg for a 70 kg adult) is only about two to four times the 30-40 mcg/kg the mice received. It is ten to twenty times the 0.5 mg per day sublingual dose that is the only human systemic figure in the review literature 5.
  • There is no dose-finding research, no maximum tolerated dose, no pharmacokinetics and no dose-response curve in humans.
  • The convention of '10 mg per day for 10-20 days' is not derived from any publication; it appears to originate from the vial size - a 10 mg vial spread over a course.
  • Any claim that a particular dose is 'the' dose is invented.

These figures describe what the literature and published protocols report. They are not advice and not a dosing instruction.

Protocols

Bioregulator course (grey market)

user protocol — not validated

Source: user protocols and vendor material

This is not a validated schedule. It is a pattern that circulates among users and sellers, reproduced because it is what people actually follow — not because it has been tested. No trial established these doses, this interval or this duration, and nobody is checking what is in the vial. Treat every number below as an assertion, not a finding.

Days 1-10, some protocols to 205-10 mg per day by subcutaneous injection
Between coursesnothing
Repeatonce or twice a year

The ten-day course looks like an artefact of the vial rather than a finding: a 10 mg vial spread over ten days. In absolute terms that is several thousand times the 1.0 mcg given per mouse in the lifespan study, but a human outweighs a mouse thousands of times over, so per kilogram it is only a few times the mouse dose, while still being ten to twenty times the only human sublingual dose in the review literature. The human outcome claims attached to this pattern were generated with Epithalamine, the crude bovine pineal extract, not with the synthetic tetrapeptide.

Schedules are reproduced as their source states them. Units, IU and milligrams explains why the figures are not interchangeable between products.

Reconstitution

Vial sizes
10 mg, 20 mg, 50 mg, 100 mg (lyophilised powder)
Solvent
bacteriostatic water (0.9% benzyl alcohol); sterile water only if used within the same session
Storage
Lyophilised powder refrigerated at 2-8 °C, protected from light; long term at -20 °C. Reconstituted at 2-8 °C and, according to suppliers, use within approximately 2-4 weeks; with plain sterile water without preservative, the same day. Avoid repeated freezing and thawing and the fridge door.

Worked example

10 mg vial + 2 ml bacteriostatic water = 5 mg/ml. 5 mg then corresponds to 1 ml, that is 100 units on a U100 insulin syringe.

Let the water run slowly down the wall, never directly onto the powder; swirl, do not shake. Do not use if cloudy or if visible particles are present. N-acetyl-epitalon amidate is a chemically different substance with even less data and is not interchangeable. These handling instructions come from suppliers and are not pharmacopoeia specifications.

Work it out for Epitalon

Safety

Side effects

  • The published clinical reports mention no side effects - the 2025 review states that none of the Epitalon-treated patients in the retinitis pigmentosa trial reported any 5 - but that reflects the absence of systematic safety monitoring in small, unblinded studies and is not evidence of safety
  • No formal toxicology programme, carcinogenicity study or reproductive toxicity study has ever been carried out. The 2025 review says as much in its own words: information on this peptide's safety is missing, and genotoxic activity, carcinogenic potential and drug-drug and food-drug interactions all still need to be studied before approval as an active substance could be considered 5
  • Reported by users, uncontrolled and unverifiable: injection site reactions, transient headache, drowsiness or altered sleep rhythm, lethargy

Do not use if

  • Active, past or suspected malignancy, known premalignant lesions or a strong family history of cancer - this is the foremost concern. Telomerase reactivation is a hallmark step in malignant transformation, and the 2025 study showed telomere elongation and ALT activation in two breast cancer cell lines 6. Carcinogenic potential has never been assessed 5
  • Pregnancy and breastfeeding - not a single data point
  • Children and adolescents - no data; disruption of telomere biology during development has not been studied
  • Hypersensitivity to the peptide or to benzyl alcohol in the diluent

Interactions

Not studied - the 2025 review names drug-drug and food-drug interactions among the things still to be investigated 5. Theoretically conceivable are additive effects with melatonin or other chronobiotics given the claimed pineal mechanism, and an unpredictable interplay with oncology treatments - in particular with telomerase-targeted agents, where the peptide would act in the opposite direction.

Common questions

What is epitalon?
Epitalon (epithalon) is a synthetic tetrapeptide from Russian bioregulator research, marketed on claims of telomerase activation and anti-ageing through the pineal gland. The human evidence is very limited and largely from a single research group.
Does epitalon actually extend lifespan or activate telomerase?
Those claims rest on a small body of mostly Russian research from one group, not on replicated, independent human trials. It is best treated as an unproven, experimental compound.
Is epitalon legal, and is it banned in sport?
It is an unapproved research chemical. It is not specifically named on the WADA list, but that is not a clearance — check doping status for your sport.

Sources